ST高升(000971) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥187,568,549.04, a decrease of 2.08% compared to the same period last year[3] - The net profit attributable to shareholders was -¥48,244,261.79, representing a significant decline of 7565.59% year-on-year[3] - The net profit after deducting non-recurring gains and losses was -¥50,637,398.52, a decrease of 790.37% compared to the previous year[3] - Total operating revenue for Q3 2021 was CNY 543,738,381.70, a decrease of 8.3% from CNY 593,069,825.06 in the same period last year[22] - Net profit for Q3 2021 was a loss of CNY 83,525,228.80, compared to a profit of CNY 11,038,290.43 in Q3 2020[24] - Basic and diluted earnings per share were both reported at -0.08, compared to 0.011 in the same quarter last year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,157,752,274.29, a slight decrease of 0.15% from the end of the previous year[4] - The total assets amounted to CNY 2,160,900,455.00, reflecting a decrease from 2,229,397,565.36 CNY at the beginning of the year[30] - The total liabilities were CNY 941,265,170.68, which is a marginal increase from CNY 937,669,410.22[20] - Total current liabilities amounted to CNY 462,173,401.15, with accounts payable at CNY 165,070,568.44 and other payables at CNY 199,101,778.16[32] - Non-current liabilities totaled CNY 475,496,009.07, primarily driven by estimated liabilities of CNY 446,196,300.00 and lease liabilities of CNY 53,352,588.46[32] - The company's total equity was reported at CNY 1,223,231,044.78, with a significant negative retained earnings of CNY -3,017,129,277.30[33] Cash Flow - Cash flow from operating activities was -¥80,444,697.67, a decrease of 5.62% compared to the previous year[3] - Cash flow from operating activities was CNY 505,915,210.35, slightly down from CNY 518,931,261.71 in the previous year[26] - Net cash flow from operating activities was -80,444,697.67 CNY, compared to -76,162,117.52 CNY in the previous year, indicating a decline in operational cash flow[27] - Total cash inflow from investment activities was 73,236,216.00 CNY, significantly higher than 126,030.80 CNY in the same period last year[28] - Cash outflow from investment activities totaled 131,255,247.38 CNY, compared to 117,911,273.15 CNY in the previous year, resulting in a net cash flow from investment activities of -58,019,031.38 CNY[28] - The ending balance of cash and cash equivalents was 111,217,923.82 CNY, down from 310,879,437.94 CNY at the end of the previous year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,678[11] - Tianjin Bai Ruoke Pharmaceutical Biotechnology Co., Ltd. holds 15.12% of shares, amounting to 158,550,396 shares, with 109,275,198 shares pledged[11] - Blue Ding Industrial (Hubei) Co., Ltd. holds 8.60% of shares, totaling 90,178,582 shares, all of which are pledged or frozen[11] Inventory and Receivables - The company’s inventory increased by 60.93% to ¥174,425,925.52, primarily due to unfinished design service contracts[8] - Accounts receivable increased from RMB 523,995,123.11 at the end of 2020 to RMB 557,779,642.72 by September 30, 2021, an increase of about 6.5%[18] - Inventory rose significantly from RMB 108,384,713.22 at the end of 2020 to RMB 174,425,925.52 by September 30, 2021, representing an increase of approximately 61.0%[18] Legal and Compliance Issues - The company has faced legal issues regarding unauthorized guarantees amounting to approximately RMB 839.64 million[14] - The company has received a debt transfer notice from Beijing Bitian Wealth Investment Co., Ltd., which has transferred its claims to Tianjin Bai Ruoke[15] - The third-quarter report was not audited, which may affect the reliability of the financial data presented[35] Other Financial Metrics - Research and development expenses for the quarter were CNY 26,778,678.17, down from CNY 28,542,981.29 in the previous year[23] - The company reported a significant increase in investment income of ¥17,501,255.63, up 17,354,751.07 compared to the same period last year[9] - The company reported a significant increase in accounts payable, rising to CNY 209,067,587.58 from CNY 165,070,568.44, reflecting a 26.7% increase[20] - The company adjusted its financial statements to comply with new leasing standards, impacting the balance sheet figures[29] - The company has adopted new leasing standards effective January 1, 2021, impacting the measurement of lease liabilities and right-of-use assets[34]